ABOG Maternal-Fetal Medicine flashcards
ABOG Maternal-Fetal Medicine · Build recall with a focused review session.
32 cards. Read the term and the definition here. The deck at the top of this page is optional.
- Superimposed preeclampsia
- New proteinuria or end-organ dysfunction after 20 weeks in a patient with chronic hypertension; delivery is definitive and timing depends on severity and gestational age.
- Low-dose aspirin prophylaxis
- 81 mg daily started before 16 weeks reduces early-onset preeclampsia in high-risk patients, including prior preeclampsia, chronic hypertension, diabetes, and multifetal gestation.
- Carpenter-Coustan criteria
- Three-hour 100-g oral glucose tolerance test thresholds for gestational diabetes: fasting 95, 1-hour 180, 2-hour 155, 3-hour 140 mg/dL; two or more abnormal values establish diagnosis.
- Perimortem cesarean timing
- In maternal cardiac arrest, left uterine displacement and continuous compressions precede perimortem cesarean, ideally within 4-5 minutes of arrest to improve maternal and fetal survival.
- Amniotic fluid embolism
- Sudden hypoxia, hypotension, and coagulopathy during labor or delivery; diagnosis is clinical and treatment is supportive with aggressive transfusion and cardiopulmonary support.
- Acute fatty liver of pregnancy
- Third-trimester nausea, jaundice, hypoglycemia, and coagulopathy from microvesicular hepatic steatosis; urgent delivery is definitive and maternal ICU support is often required.
- Magnesium sulfate toxicity
- Progression from loss of deep tendon reflexes to respiratory depression and cardiac arrest; calcium gluconate 1 g IV is the antidote and infusion should be stopped.
- Postpartum hemorrhage definition
- Cumulative quantified blood loss greater than 1000 mL or bleeding with hemodynamic instability; uterotonics, tranexamic acid, and escalation follow in sequence.
- Shoulder dystocia sequence
- McRoberts maneuver and suprapubic pressure first, then internal rotation, posterior arm delivery, and finally cephalic replacement or cleidotomy if needed.
- Uterine tachysystole
- More than five contractions in ten minutes averaged over thirty minutes; reduce or stop oxytocin and consider tocolysis while monitoring the fetal heart tracing.
- Category III fetal tracing
- Absent baseline variability with recurrent decelerations or bradycardia; requires prompt evaluation and often expedited delivery given risk of fetal acidemia.
- Placenta accreta spectrum
- Abnormal trophoblast invasion into myometrium or beyond; planned cesarean hysterectomy at 34-36 weeks by a multidisciplinary team reduces hemorrhage morbidity.
- TTTS diagnostic criteria
- Donor twin with deepest vertical pocket under 2 cm and stuck twin, recipient with pocket over 8 cm; Quintero staging guides fetoscopic laser therapy.
- Twin reversed arterial perfusion
- Acardiac twin perfused by the pump twin through placental anastomoses; intrafetal radiofrequency ablation or cord occlusion is used when cardiac failure develops.
- Middle cerebral artery Doppler
- Peak systolic velocity greater than 1.5 multiples of the median suggests fetal anemia and is the trigger for intrauterine transfusion in alloimmunization.
- RhD immune globulin
- 300 mcg anti-D given at 28 weeks and within 72 hours postpartum to RhD-negative unsensitized patients prevents alloimmunization and hemolytic disease.
- FETO for diaphragmatic hernia
- Fetoscopic tracheal occlusion for severe left congenital diaphragmatic hernia improves survival but increases preterm premature rupture of membranes and preterm birth.
- Cell-free DNA screening
- Maternal plasma screening with sensitivity above 99% for trisomy 21; it remains a screening test and diagnostic confirmation requires amniocentesis or chorionic villus sampling.
- Fragile X premutation
- 55-200 CGG repeats; maternal premutation can expand to full mutation above 200 repeats in offspring, causing intellectual disability and behavioral features.
- Chromosomal microarray
- Detects submicroscopic deletions and duplications and is preferred over karyotype for fetuses with structural anomalies or unexplained developmental delay.
- Folic acid recurrence prevention
- 4 mg daily started before conception reduces neural tube defect recurrence risk by about 70% in women with a previously affected pregnancy.
- Nuchal translucency threshold
- Measurement above 3.5 mm warrants anatomic survey, fetal echocardiography, and genetic evaluation even when karyotype is normal.
- Oligohydramnios definition
- Deepest vertical pocket under 2 cm; polyhydramnios is a pocket over 8 cm, and amniotic fluid index thresholds are 5 cm and 24 cm respectively.
- Ductus venosus a-wave
- Absent or reversed a-wave indicates severe placental insufficiency and elevated stillbirth risk, often prompting intensified surveillance or delivery.
- Short cervical length
- Cervical length under 25 mm at 16-24 weeks in a singleton predicts preterm birth; cerclage or vaginal progesterone may be offered based on history.
- Group B Streptococcus prophylaxis
- Universal rectovaginal screening at 36 0/7-37 6/7 weeks; intrapartum penicillin G is first-line prophylaxis for colonized patients.
- Congenital cytomegalovirus
- Most common congenital viral infection; primary maternal infection carries the highest transmission and sequelae risk including hearing loss and neurodevelopmental delay.
- Maternal syphilis treatment
- Penicillin G is the only proven regimen; penicillin-allergic pregnant patients should undergo desensitization rather than receive alternative antibiotics.
- Neuraxial timing with heparin
- Hold low-molecular-weight heparin at least 12 hours (prophylactic) or 24 hours (therapeutic) before neuraxial placement to reduce epidural hematoma risk.
- Postdural puncture headache
- Positional headache after dural puncture; conservative therapy and caffeine first, with epidural blood patch for persistent symptoms.
- Lipid emulsion rescue
- For local anesthetic systemic toxicity, stop injection, support the airway, and give 20% lipid emulsion 1.5 mL/kg bolus followed by infusion.
- Number needed to treat
- One divided by the absolute risk reduction; number needed to harm is one divided by the absolute risk increase, both expressing clinical effect magnitude.